CA2801020A1 — A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
Assigned to Pharmascience Inc · Expires 2011-12-01 · 14y expired
What this patent protects
The present invention is directed to a stable pharmaceutical formulation comprising telmisartan, or a pharmaceutically acceptable salt thereof/ and a diuretic dispersed in a matrix. The matrix comprises at least one disinte grant in an amount ranging from 0.5 % to 20% by weight; …
USPTO Abstract
The present invention is directed to a stable pharmaceutical formulation comprising telmisartan, or a pharmaceutically acceptable salt thereof/ and a diuretic dispersed in a matrix. The matrix comprises at least one disinte grant in an amount ranging from 0.5 % to 20% by weight; a dissolution enhancing agent present in a molar ratio of dissolution enhancing agent to telmisartan of from 1:1 to 10:1; a water-insoluble diluent in an amount ranging from 15%-75% by weight and at least one other pharmaceutically acceptable excipient /or adjuvant in an amount ranging from 0 - 25% by weight,
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.